Theravance Biopharma (TBPH) Institutional Ownership

99.10% of Theravance Biopharma's stock is owned by institutional investors. Learn more on TBPH's institutional investor holdings.

Of the 139 institutional investors that purchased Theravance Biopharma's stock in the last 24 months, the following investors and hedge funds have bought the highest volume of shares: Arrowstreet Capital Limited Partnership ($726.78K), California State Teachers Retirement System ($670.58K), Assenagon Asset Management S.A. ($414.72K), JPMorgan Chase & Co. ($398.11K), Nuveen LLC ($374.95K), Dimensional Fund Advisors LP ($356.85K), and Pacer Advisors Inc. ($338.96K).

Institutional investors have bought a total of 7,449,481 shares in the last 24 months. This purchase volume represents approximately $123.88M in transactions.

Of the 46 institutional investors that sold Theravance Biopharma's stock in the last 24 months, the following investors and hedge funds have sold the highest volume of shares: Park West Asset Management LLC ($1.62M), Newtyn Management LLC ($1.41M), Arrowstreet Capital Limited Partnership ($635.71K), Citadel Advisors LLC ($434.46K), Oasis Management Co Ltd. ($391.77K), Tudor Investment Corp ET AL ($291.03K), and GSA Capital Partners LLP ($79.57K).

Institutional investors have sold a total of 5,357,307 shares in the last 24 months. This volume of shares sold represents approximately $90.12M in transactions.